US-based injectable medicine technology developer Common Sensing has completed a $6.6m series A round that included drug injection device maker Haselmeier and healthcare technology manufacturer Royal Philips.
Healthcare technology and services-focused venture capital fund Waterline Ventures led the round, which also featured VC firm New World Health.
Founded in 2012, Common Sensing has created a product called Gocap that converts injector pens into smart, connected injectors. The technology could be used to enhance the delivery of substances such as insulin, fertility hormone and human growth hormone.
The company had previously raised $1.1m in equity and $3.2m in debt financing according to securities filings. It is a past participant in Philips’ accelerator scheme, Philips HealthWorks Startup Program.
Kevin Schmid, Common Sensing’s chief operating officer, said: “This financing allows us to launch the commercial activities and manufacturing operations necessary to support our growing customer base.
“I have seen the impact that precision insulin dosing can have on the lives of people with diabetes, and it is time to put that capability into millions of hands.”